# Treatment of Metastatic Cancer in Terminally Diagnosed Patients

> **NCT05491928** · — · AVAILABLE · sponsor: **Matrix Biomed, Inc.**

## Conditions studied

- Metastatic Cancer

## Interventions

- **DRUG:** Tempol

## Key facts

- **NCT ID:** NCT05491928
- **Lead sponsor:** Matrix Biomed, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05491928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05491928, "Treatment of Metastatic Cancer in Terminally Diagnosed Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05491928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*